Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Cost efficiency and effectiveness of biosimilar filgrastim in autologous transplant

Bone Marrow Transplantation volume 57, pages 312–314 (2022)Cite this article

Subjects

Biosimilars are strategic tools to contain the growing costs of health care systems by achieving comparable safety and efficacy as compared to originator molecules[1]. However, they are not identical copies of their corresponding originators and cannot be considered “generics”[2].

Granulocyte colony-stimulating factors (G-CSFs) are biological compounds used to treat chemotherapy-induced neutropenia, to facilitate engraftment after hematopoietic stem cell transplantation, and to mobilize peripheral blood progenitor cell (PBPC)[3, 4].

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Renwick MJ, Smolina K, Gladstone EJ, Weymann D, Morgan SG. Postmarket policy considerations for biosimilar oncology drugs. Lancet Oncol. 2016;17:e31–8.

    Article  Google Scholar 

  2. Daller J. Biosimilars: A consideration of the regulations in the United States and European union. Regul Toxicol Pharm. 2016;76:199–208.

    Article  Google Scholar 

  3. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187–205.

    Article  CAS  Google Scholar 

  4. Cottler-Fox MH, Lapidot T, Petit I, Kollet O, DiPersio JF, Link D, et al. Stem cell mobilization. Hematology Am Soc Hematol Educ Program. 2003:419–37.

  5. Waller CF, Semiglazov VF, Tjulandin S, Bentsion D, Chan S, Challand R. A phase III randomized equivalence study of biosimilar filgrastim versus Amgen filgrastim in patients receiving myelosuppressive chemotherapy for breast cancer. Onkologie 2010;33:504–11.

    CAS  PubMed  Google Scholar 

  6. Shaw BE, Confer DL, Hwang WY, Pamphilon DH, Pulsipher MA. Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association. Haematologica 2011;96:942–7.

    Article  Google Scholar 

  7. Elayan MM, Horowitz JG, Magraner JM, Shaughnessy PJ, Bachier C. Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation. Biol Blood Marrow Transpl. 2015;21:1921–5.

    Article  CAS  Google Scholar 

  8. Bassi S, Stroppa EM, Moroni CF, Arbasi MC, Trabacchi E, Di Franco A, et al. Safety and efficacy of granulocyte colony-stimulating factor biosimilars in engraftment after autologous stem cell transplantation for haematological malignancies: a 4-year, single institute experience with different conditioning regimens. Blood Transfus. 2015;13:478–83.

    PubMed  PubMed Central  Google Scholar 

  9. Marchesi F, Cerchiara E, Dessanti ML, Gumenyuk S, Franceschini L, Palombi F, et al. Comparison between biosimilar filgrastim vs other granulocyte-colony stimulating factor formulations (originator filgrastim, peg-filgrastim and lenograstim) after autologous stem cell transplantation: a retrospective survey from the Rome Transplant Network. Br J Haematol. 2015;169:293–6.

    Article  CAS  Google Scholar 

  10. Ianotto JC, Tempescul A, Yan X, Delepine P, Le Calloch R, Hardy E, et al. Experience (1 year) of G-CSF biosimilars in PBSCT for lymphoma and myeloma patients. Bone Marrow Transpl. 2012;47:874–6.

    Article  Google Scholar 

  11. Gascon P. Presently available biosimilars in hematology-oncology: G-CSF. Target Oncol 2012;7:S29–34.

    Article  Google Scholar 

  12. Italian Medicines Agency. The Medicines Utilisation Monitoring Centre (OsMed). National report on medicines use in Italy. Year 2015. Rome: OsMed; 2016, p. 566.

Download references

Acknowledgements

This work was supported by Fondi di Ricerca Locale, Università degli Studi di Torino, Torino, Italy and by Fondazione Neoplasie del sangue (FO.NE. SA),Torino, Italy. The authors would like to thank Maria Josè Fornaro, Antonella Fiorillo and Franca Trotto Gatta for excellent secretarial support.

Author information

Authors and Affiliations

  1. Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, University of Torino, Torino, Italy

    Luisa Giaccone, Lucia Brunello, Marco Cerrano, Valter Redoglia, Paola Omedè, Giuseppe Lia, Dario Ferrero, Federica Cavallo, Sara Bringhen, Mario Boccadoro & Benedetto Bruno

  2. Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy

    Luisa Giaccone, Lucia Brunello, Marco Cerrano, Valter Redoglia, Giuseppe Lia, Massimo Massaia, Dario Ferrero, Federica Cavallo, Mario Boccadoro & Benedetto Bruno

  3. Division of Hematology and Medical Oncology, Perlmutter Cancer Center, NYU Grossman School of Medicine, NYU Langone Health, New York, NY, USA

    Jaime Suarez Londono & Benedetto Bruno

  4. Pharmacy, A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy

    Matilde Scaldaferri & Francesco Cattel

  5. Department of Internal Medicine, NYU Grossman School of Medicine, New York, NY, USA

    Sarah Leone

  6. Blood bank and immunohematology, A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy

    Tiziana Francisci & Valter Tassi

  7. Unit of clinical epidemiology, A.O.U. Città della Salute e della Scienza di Torino, University of Torino, Torino, Italy

    Andrea Evangelista

Authors
  1. Luisa Giaccone
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lucia Brunello
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jaime Suarez Londono
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Matilde Scaldaferri
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marco Cerrano
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Valter Redoglia
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Paola Omedè
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Giuseppe Lia
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Massimo Massaia
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Dario Ferrero
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Federica Cavallo
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Sara Bringhen
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Sarah Leone
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Francesco Cattel
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Tiziana Francisci
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Valter Tassi
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Andrea Evangelista
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Mario Boccadoro
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Benedetto Bruno
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

L.G., M.B., and B.B. designed the study. L.G. and B.B. wrote the report. B.B. supervised the clinical conduction of the study and data analysis. L.B. collected data. B.B., L.G., L.B., M.M., D.F., F.C., G.L., and S.B. recruited the patients and supervised data collection. M.S. and F.C. provided cost analysis. T.F., P.O., V.R., and V.T. provided stem cell collection, mobilization data. M.B., M.M., J.S.L., S.L., B.B., and L.G., and reviewed and assisted in writing the manuscript. A.E. did the statistical analysis.

Corresponding author

Correspondence to Luisa Giaccone.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Giaccone, L., Brunello, L., Londono, J.S. et al. Cost efficiency and effectiveness of biosimilar filgrastim in autologous transplant. Bone Marrow Transplant 57, 312–314 (2022). https://doi.org/10.1038/s41409-021-01541-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-021-01541-1

Search

Advanced search

Quick links